Evolution of the Average Target: UCB

Evolution of the Target Price: UCB

Changes in Analyst Recommendations: UCB

3f686bf5.J7CPuMxGbFovVnd0XdopxZiUeOvC7zNHPpazLoNSMLI.TO_335UkWxRCFREeZJtBicDEDN6Yo3d3UND7Z_cfauMR5dbzpXMKd2APRw~ff78976ca8e576babad0363be1f20b3a
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-18 UCB: An unimpressive upgrade-led correction opens a rare opportunity Alphavalue
08-11 Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed MT
08-11 UCB barely moves despite positive calls from ING and Berenberg Zonebourse
07-31 AlphaValue/Baader Europe Upgrades UCB to Add, Trims PT MT
07-30 Kempen Upgrades UCB to Buy Rating, Boosts PT MT
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-03 Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals MT
06-22 UBS Trims UCB's PT, Affirms Buy Rating MT
06-15 UCB Slumps Following Analyst Downgrade Zonebourse
06-15 Barclays Downgrades UCB to Equalweight, Trims PT MT
06-15 UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum MT
06-09 UCB Favored by Oddo BHF Zonebourse
06-05 KBC Securities Maintains Buy Rating on UCB Zonebourse
05-21 UCB Price Target, Estimates Up as AlphaValue/Baader Europe Notes Growth Momentum MT
05-20 UCB: Executing well, but valuation lacks safety net Alphavalue
04-27 AlphaValue/Baader Europe Upgrades UCB to Reduce, Trims PT MT
03-30 MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says MT
03-16 Berenberg says Belgian drugmaker UCB stock is undervalued Zonebourse
03-16 Berenberg Keeps UCB Amid Positive Pipeline Progress, H2 Catalysts MT
02-26 UCB: H2 beat; 2026 outlook healthy; but valuation remains red-hot Alphavalue
02-24 Wolfe Research Kicks Off UCB Coverage at Outperform MT
02-02 UCB on Track for 'Impressive' Growth Acceleration, Says RBC MT
01-07 BofA Reaffirms UCB's Buy Rating on Upbeat FY26 Outlook MT
01-06 Analysts' calls of the day: Bernstein favors Thales over BAE Systems and Dassault Aviation Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+5.17%
-4.66%
-19.8%
+29.88%
+32.5%
+9.03%
+3.17%
+23.78%
+10.62%
Average +9.97%
Weighted average by Cap. +8.21%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
218.50EUR
Average target price
285.00EUR
Spread / Average Target
+30.43%
High Price Target
340.00EUR
Spread / Highest target
+55.61%
Low Price Target
208.00EUR
Spread / Lowest Target
-4.81%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA